

Press news Biocartis Group NV: Biocartis and Exact Sciences Agree to End Collaboration Due to Changed Market Circumstances

Biocartis Group NV <donotreply-eu@globenewswire.com>

Do 29/10/2020 16:46

Aan: Vfb Persberichten <persberichten@vfb.be>

PRESS RELEASE: REGULATORY INFORMATION – INSIDE INFORMATION
29 October 2020, 16:45 CET

Biocartis and Exact Sciences Agree to End Collaboration Due to Changed Market Circumstances

Mechelen, Belgium, 29 October 2020 – Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company (Euronext Brussels: BCART), today announces that Biocartis and Genomic Health, Inc. (a subsidiary of Exact Sciences Corporation) have agreed to terminate their collaboration, which was focused on the development of the Oncotype DX Breast Recurrence Score[®] test on Biocartis’ molecular diagnostics platform Idylla[™].

As a result of COVID-19, the project had been suspended earlier during 2020, with the project plan and timing under evaluation. The decision to now terminate the collaboration was driven by the uncertain timing of a product market release because of the pandemic and a decision by Exact Sciences to shift priorities to other initiatives.

Herman Verrelst, Chief Executive Officer of Biocartis, reacted: *“We regret that this collaboration has ended, but we respect the decision that has been made by Exact Sciences. The impact of this termination to our future growth is contained, as the collaboration was limited to the European market in which we already offer a comprehensive menu of tests to our well-established customer base. Also, this termination will have no impact on our ambitions to grow in the US and in our export markets. Similarly, the termination will not affect the financial performance in 2020 other than as a result of the settlement. We remain very confident in the broader partner strategy we built out over the last years and look forward to collaborate with several other partners and bring their novel tests to the market on our Idylla[™] platform.”*

As part of a termination settlement, Genomic Health, Inc. agreed to pay USD 12 million to Biocartis and license certain rights and transfer certain assets to Biocartis.

--- END ---

More information:

Renate Degrave

Head of Corporate Communications & Investor Relations Biocartis

e-mail rdegrave@biocartis.com

tel +32 15 631 729

mobile +32 471 53 60 64

About Biocartis

Biocartis (Euronext Brussels: BCART) is an innovative molecular diagnostics (MDx) company providing next generation diagnostic solutions aimed at improving clinical practice for the benefit of patients, clinicians, payers and industry. Biocartis' proprietary MDx Idylla[™] platform is a fully automated sample-to-result, real-time PCR (Polymerase Chain Reaction) system that offers accurate, highly reliable molecular information from virtually any biological sample in virtually any setting. Biocartis is developing and marketing a continuously expanding test menu addressing key unmet clinical needs, with a focus in oncology, which represents the fastest growing segment of the MDx market worldwide. Today, Biocartis offers tests supporting melanoma, colorectal and lung cancer. More information: www.biocartis.com. Follow us on [@Biocartis_](https://twitter.com/Biocartis_).

Biocartis and Idylla™ are registered trademarks in Europe, the United States and other countries. The Biocartis and Idylla™ trademark and logo are used trademarks owned by Biocartis. This press release is not for distribution, directly or indirectly, in any jurisdiction where to do so would be unlawful. Any persons reading this press release should inform themselves of and observe any such restrictions. Biocartis takes no responsibility for any violation of any such restrictions by any person. Please refer to the product labeling for applicable intended uses for each individual Biocartis product. This press release does not constitute an offer or invitation for the sale or purchase of securities in any jurisdiction. No securities of Biocartis may be offered or sold in the United States of America absent registration with the United States Securities and Exchange Commission or an exemption from registration under the U.S. Securities Act of 1933, as amended.

Forward-looking statements

Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company's or, as appropriate, the Company directors' or managements' current expectations and projections concerning future events such as the Company's results of operations, financial condition, liquidity, performance, prospects, growth, strategies and the industry in which the Company operates. By their nature, forward-looking statements involve a number of risks, uncertainties, assumptions and other factors that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties, assumptions and factors could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward-looking statements contained in this press release regarding past trends or activities are not guarantees of future performance and should not be taken as a representation that such trends or activities will continue in the future. In addition, even if actual results or developments are consistent with the forward-looking statements contained in this press release, those results or developments may not be indicative of results or developments in future periods. No representations and warranties are made as to the accuracy or fairness of such forward-looking statements. As a result, the Company expressly disclaims any obligation or undertaking to release any updates or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based, except if specifically required to do so by law or regulation. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.

This message was distributed by Nasdaq's GlobeNewswire.
(165 Broadway, New York, NY, 10006, USA, 1.212.401.8700, www.nasdaq.com)
On behalf of **Biocartis NV** **Generaal De Wittelaan 11 B3, Mechelen, 2800 BE**

This message was sent to persberichten@vfb.be.
If you wish to no longer receive these messages you can [unsubscribe](#).